{"id":"W4417452850","doi":"10.1038/s41433-025-04161-x","title":"TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration","year":2025,"lang":"en","type":"article","venue":"Eye","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharma","keywords":"Macular degeneration; Aflibercept; Eye disease; Maculopathy; Fluorescein angiography; Ranibizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001139938,0.000164899,0.0003387078,0.0001202653,0.0001117878,0.00001913054,0.00004171632,0.00007081845,0.00002163839],"category_scores_gemma":[0.0001005497,0.0001404995,0.0001876657,0.0002027098,0.00005188853,0.00005759312,0.00002619704,0.00005742281,0.000002742215],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008616784,"about_ca_system_score_gemma":0.00007168119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002696335,"about_ca_topic_score_gemma":0.00001897434,"domain_scores_codex":[0.9989231,0.00005217019,0.0003392963,0.0003292116,0.0001855797,0.000170684],"domain_scores_gemma":[0.9993788,0.00004795303,0.00009108541,0.0003004174,0.00009206007,0.00008969611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2455127,0.04768271,0.02444744,0.002143701,0.02076375,0.004895629,0.00891618,0.002724489,0.1367778,0.001534392,0.005709006,0.4988921],"study_design_scores_gemma":[0.6442907,0.03234328,0.1910513,0.001511024,0.03037334,0.00004628347,0.002952164,0.04919796,0.0370405,0.0008659596,0.009075629,0.001251756],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995599,0.001470792,0.0002486265,0.0001184896,0.0001389168,0.00119294,0.00007199785,0.00003134437,0.001127921],"genre_scores_gemma":[0.9965976,0.00005310383,0.0007703495,0.00002268865,0.00004013769,0.0000368403,0.0003590102,0.00001934679,0.002100947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4976404,"threshold_uncertainty_score":0.5729403,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0407381807064018,"score_gpt":0.3793422191944776,"score_spread":0.3386040384880759,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}